Definium Therapeutics (NASDAQ:DFTX) Trading Down 5.6% – What’s Next?

Definium Therapeutics, Inc. (NASDAQ:DFTX) fell 5.6% during mid-day trading on Tuesday . The company traded as low as $37.93 and last traded at $38.01. 804,683 shares were traded during trading, a decline of 64% from the average daily volume of 2,245,351 shares. The stock had previously closed at $40.25.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported a second successful Phase 3 trial for DT120 orally disintegrating tablets in generalized anxiety disorder. The treatment produced statistically significant improvements in anxiety symptoms, supporting the company’s plans to engage with the FDA and pursue a potential 2027 regulatory filing. Definium Reports Second Phase III Success
• Positive Sentiment: Robert W. Baird raised its price target for DFTX from $75 to $79 and maintained an “outperform” rating, implying substantial potential upside from the stock’s recent trading level. Baird Raises Definium Price Target
• Positive Sentiment: HC Wainwright reiterated its “buy” rating, while Needham & Company also assigned a “buy” rating. The recommendations indicate continued Wall Street confidence in Definium’s clinical and commercial prospects. HC Wainwright Reiterates Buy Rating Needham Gives Definium a Buy Rating
• Positive Sentiment: Healthcare-focused commentary described analysts as bullish on Definium and suggested the shares could trade at a premium after the Phase 3 success, with another analysis characterizing the stock as undervalued. Analysts Are Bullish on Definium Definium Still Looks Undervalued
• Negative Sentiment: Traders purchased a large volume of DFTX put options, signaling that some market participants are positioning for downside or hedging against volatility. This is a cautionary counterpoint to the predominantly bullish analyst coverage. Large Definium Put-Option Activity

Analyst Ratings Changes

A number of brokerages have weighed in on DFTX. Wells Fargo & Company upped their price target on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a report on Monday. Robert W. Baird boosted their price objective on shares of Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of Definium Therapeutics in a research note on Monday. Finally, Maxim Group set a $55.00 target price on Definium Therapeutics and gave the company a “buy” rating in a research report on Friday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $64.88.

Definium Therapeutics Trading Up 2.8%

The firm has a market cap of $5.09 billion, a P/E ratio of -11.03 and a beta of 2.23. The business’s 50-day moving average is $42.62 and its two-hundred day moving average is $30.77. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, analysts predict that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider owned 320,571 shares in the company, valued at $14,435,312.13. The trade was a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 67,119 shares of company stock worth $2,887,496 over the last 90 days. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP acquired a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $138,755,000. Avoro Capital Advisors LLC acquired a new position in Definium Therapeutics during the fourth quarter worth $66,950,000. Bank of New York Mellon Corp increased its holdings in Definium Therapeutics by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after buying an additional 24,349 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in Definium Therapeutics during the second quarter worth $6,992,000. Finally, Seven Grand Managers LLC bought a new stake in Definium Therapeutics during the fourth quarter worth $3,013,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.